Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
About this email
Captured Announcement
Takeda announces positive Phase 3 clinical trial results for Arcotatug Tavatecan (TAK-921) in advanced gastric cancer.
Top header with logo banner above a split press release banner featuring lab imagery, followed by the news headline, text CTA, and an interactive feedback poll.
Color palette
Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.
